While molecular targeted therapies, such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors, have significantly helped patients with specific genetic alterations, only a minority of patients with NSCLC have these mutations [11]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.